Literature DB >> 19946100

Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.

P B Aleixo1, A A Hartmann, I C Menezes, R T Meurer, A M Oliveira.   

Abstract

BACKGROUND: Well differentiated liposarcomas (WDLPS) and dedifferentiated liposarcomas (DDLPS) have been shown to have supernumerary chromosomes with amplified sequences of the MDM2 and CDK4 genes. MDM2 and CDK4 protein overexpression have also been identified in these tumours. AIM: To investigate whether immunohistochemistry (IHC) for MDM2 and CDK4 can be used to diagnose WDLPS and DDLPS.
METHODS: IHC for MDM2/CDK4 was carried out on a series of 129 paraffin-embedded lipomatous and non-lipomatous soft tissue tumours. The cases were divided into four groups: WDLPS (n = 19), DDLPS (n = 10), benign adipocytic tumours (BAT) (n = 17), and other mesenquimal tumours (OMT) (n = 83). IHC results were compared in each group and the diagnostic efficacy of the test in identifying WDLPS and DDLPS among the other soft tissue tumours was determined. A percentage of tumour cell positivity was evaluated to better characterise the pattern of tumour immunostaining.
RESULTS: Sensitivity and specificity of positive MDM2 and CDK4 immunostainings to identify WDLPS among BAT was 100% and 58.8%, and 68.4% and 88.2%, respectively. When distinguishing DDLPS from OMT, sensitivity and specificity of MDM2 and CDK4 were 90% and 65%, and 70% and 96.3%, respectively. The highest specificity was achieved when a case was considered positive with strong and diffuse immunoreactivity in more than 30% of the neoplastic cells (94.1% and 100%, and 77.1% and 98.8%, respectively).
CONCLUSION: Detection of MDM2/CDK4 protein overexpression by IHC can be used by pathologists to diagnose WDLPS and DDLPS. Considering a strong and diffuse immunostaining pattern in most of the neoplastic cells achieves the best results in identifying these tumours.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19946100     DOI: 10.1136/jcp.2009.070201

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  35 in total

1.  Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.

Authors:  Bin Jia; Edwin Choy; Gregory Cote; David Harmon; Shunan Ye; Quancheng Kan; Henry Mankin; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Lett       Date:  2013-09-02       Impact factor: 8.679

2.  The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma.

Authors:  Abberly Lott Limbach; Mark W Lingen; James McElherne; Heather Mashek; Carrie Fitzpatrick; Elizabeth Hyjek; Reza Mostofi; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2020-02-05

3.  HIF-1α, MDM2, CDK4, and p16 expression in ischemic fasciitis, focusing on its ischemic condition.

Authors:  Yuichi Yamada; Izumi Kinoshita; Kenichi Kohashi; Hidetaka Yamamoto; Yuki Kuma; Takamichi Ito; Kenji Koda; Atsushi Kisanuki; Manabu Kurosawa; Michiko Yoshimura; Masutaka Furue; Yoshinao Oda
Journal:  Virchows Arch       Date:  2017-05-06       Impact factor: 4.064

4.  Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics.

Authors:  Hiroaki Kimura; Yoh Dobashi; Takayuki Nojima; Hiroyuki Nakamura; Norio Yamamoto; Hiroyuki Tsuchiya; Hiroko Ikeda; Seiko Sawada-Kitamura; Takeru Oyama; Akishi Ooi
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

Review 5.  Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.

Authors:  Jun Lu; David Wood; Evan Ingley; Sulev Koks; Daniel Wong
Journal:  Mol Biol Rep       Date:  2021-04-24       Impact factor: 2.316

Review 6.  Combining targeted agents with modern radiotherapy in soft tissue sarcomas.

Authors:  Philip Wong; Peter Houghton; David G Kirsch; Steven E Finkelstein; Arta M Monjazeb; Meng Xu-Welliver; Adam P Dicker; Mansoor Ahmed; Bhadrasain Vikram; Beverly A Teicher; C Norman Coleman; Mitchell Machtay; Walter J Curran; Dian Wang
Journal:  J Natl Cancer Inst       Date:  2014-10-18       Impact factor: 13.506

7.  A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions.

Authors:  Florence Pedeutour; Georges Maire; Anne Pierron; David M Thomas; Dale W Garsed; Laurence Bianchini; Valérie Duranton-Tanneur; Annabelle Cortes-Maurel; Antoine Italiano; Jeremy A Squire; Jean-Michel Coindre
Journal:  Virchows Arch       Date:  2012-06-08       Impact factor: 4.064

Review 8.  Emerging therapeutic targets for soft tissue sarcoma.

Authors:  Jason L Smith; Richard F Riedel
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075

9.  Can HMGI-C be used as an aid with MDM2 and CDK4 to differentiate liposarcoma subtypes from their mimics?

Authors:  Hanan Alshenawy
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-26       Impact factor: 4.553

10.  Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study.

Authors:  M Toulmonde; A Le Cesne; S Piperno-Neumann; N Penel; C Chevreau; F Duffaud; C Bellera; A Italiano
Journal:  Ann Oncol       Date:  2015-06-03       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.